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mutant  has  remained  fairly  stable  in  Ghana  several  years  after  ofﬁcial  disuse  of
chloroquine.  Certain  mutations  in  Pfmdr1  may  potentiate  Pfcrt  T76,  offering  a
possible  explanation  for  this  observation.  To  understand  the  phenomenon,  the  co-
existence  of  mutations  in  Pfmdr1  with  Pfcrt  T76  in  Ghanaian  Plasmodium  falciparum
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everal  years  after  the  replacement  of  chloroquine
s a  ﬁrst  line  antimalarial  drug  in  Malawi,  Ethiopia
nd Tanzania,  among  others,  chloroquine  (CQ)  sen-
itive Plasmodium  falciparum  has  recovered  [1—4].
he re-emergence  of  CQ-sensitive  P.  falciparum
esulted from  an  increased  dominance  of  wild-type
arasites that  have  lysine  at  codon  76  of  the  Pfcrt
ene [5—8].  Interestingly,  the  period  of  this  recov-
ry coincided  with  a  reduction  in  point  mutations
f the  Pfmdr1  genes,  such  as  Asn86Tyr,  Asn1042Asp
nd Asp1246Tyr  [9].  This  observation  strongly  sug-
ests a  possible  link  of  Pfcrt  with  Pfmdr1  mutations
n a  modulation  of  the  sensitivity  of  P.  falciparum
o CQ.
In  our  previous  report,  we  showed  the  main
Q resistant  marker  K76T  of  the  Pfcrt  gene  has
emained fairly  stable  with  a  gradual  decrease  in
ertain parts  of  Ghana  compared  to  Malawi  [10,11].
ersistence of  chloroquine  resistant  parasites  in
hana after  the  changes  in  anti-malarial  drug  poli-
ies has  also  been  observed  in  other  countries
12—14].  Though  the  prevalence  of  mutations  in  the
fcrt gene  on  chromosome  7  and  the  Pfmdr1  gene
n chromosome  5  has  been  determined  individually
n Ghana,  the  interplay  between  them  has  yet  to  be
ssessed and  discussed  in  detail.  Study  is  needed
ue to  reports  that  indicate  both  Pfmdr1  gene
uplication and  mutations  at  codons  86,  184,  1034,
S
T
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orted  presence  of  parasites  with  reduced  sensitivity  to
the  country  was  also  studied.  Blood  samples  collected
nts  presenting  at  health  facilities  in  two  distinct  ecolog-
e  prevalence  of  Pfcrt  K76T  and  the  ﬁve  point  mutations
using  nested  PCR  followed  by  RFLP  analysis.  The  associ-
termined  by  chi  square  analysis,  and  synergism  between
ed  using  the  Jonckheere—Terptra  (J—T)  test  followed  by
).  Nearly  ﬁfty-four  percent  (53.7%)  of  the  P.  falciparum
crt  T76  gene,  out  of  which  18.3%  had  both  K76  and  T76
86,  184,  1034,  1042  and  1246  of  the  Pfmdr1  gene  were
1.0%,  91.6%  and  8.4%  of  the  isolates,  respectively.  The
t  were  NFCDD  (43.46%),  YFCDD  (27.57%),  NFSDD  (7.48%),
67%).  Pfcrt  T76  was  signiﬁcantly  associated  with  a  double
 of  Pfmdr1  (YF;  2 =  18.045,  p  =  0.006).  Associations  were
 and  Pfmdr1  triple  mutation  at  codons  86,  184  and  1034
nd  YFC;  2 =  16.489,  p  =  0.011).  The  J—T  test  showed  sig-
Pfcrt  76  and  Pfmdr1  polymorphisms  (p  <  0.0001),  which
 CI.  Synergism  between  Pfcrt  and  Pfmdr1  mutant  genes
covery  of  chloroquine  sensitive  P.  falciparum  in  Ghana.
 explain  resistance  to  amodiaquine  and  quinine.  The  out-
cated  a  possible  emergence  of  artemether-lumefantrine
ziz  University  for  Health  Sciences.  Published  by
served.
042  and  1246  are  associated  with  resistance  to
hloroquine,  meﬂoquine,  quinine  and  artemisinin
erivatives [12,15,16]. Of  particular  interest  is how
ifferent haplotypes  of  Pfmdr1  contribute  to  spe-
iﬁc antimalarial  drug  resistance.  Speciﬁcally,  the
ombined  effect  of  Y184F,  N1042D  and  D1246Y
FDY) haplotype  isolates  from  Africa,  Asia  and  South
merica have  been  reported  to  be  associated  with
Q resistance  phenotypes  [17—19]. Additionally,
tudy is  needed  for  the  S1034C,  N1042D  and  D1246Y
CDY)  isolates  from  South  America  that  are  asso-
iated  with  quinine  resistance  [20],  as  well  as  for
he N86,  F184  and  D1246  (NFD)  isolates  from  Tan-
ania and  Mozambique  that  are  associated  with
rtemether  lumefantrine  recrudescence  [21,22].
This study  investigated  the  impact  of  the  com-
ined mutations  in  the  Pfmdr1  and  Pfcrt  mutant
enes  on  the  delayed  restoration  of  sensitivity  of
alarial parasites  to  CQ  in  Ghana.  Additionally,
he study  sought  an  explanation  for  the  reports  of
ncreasing  levels  of  P.  falciparum  resistance  to  qui-
ine and  amodiaquine.
ethods
tudy siteshis  report  describes  a  cross-sectional  study  con-
ucted in  Ghana  health  facilities  located  in  areas
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Figure  1  Map  of  the  Central  Region  of  Ghana.  Map  showing  the  district  where  the  study  was  conducted  (insert  is  the
).
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participate. The  purpose  of  the  study  was  explainedmap  of  Ghana  showing  the  position  of  the  Central  Region
representing  two  distinct  ecological  zones,  both
forest and  coastal.  The  facilities  are  the  Twifo  Praso
district and  St.  Francis  Xavier  hospitals  located  in
the forest  zone,  and  the  Cape  Coast  Metropolitan
hospital and  Elmina  health  center  which  are  located
in the  coastal  zone  (Fig.  1).  Apart  from  ecology,
other considerations  for  selection  of  these  sites
were  based  on  malaria  endemicity,  prevalence  of
Pfcrt 76T  mutations  and  the  level  of  chloroquine
usage as  determined  in  our  previous  study  [10].
As in  other  areas  in  Ghana,  treatment
of febrile  illness  with  chloroquine  was  the
mainstay of  malaria  control  until  2005  when
ﬁeld-based evidence  indicated  the  presence  of
P. falciparum  isolates  resistant  to  the  drug.  Based
on this  evidence,  and  upon  the  recommenda-
tion of  the  WHO  and  other  organizations,  in
2005 Ghana  ofﬁcially  changed  from  the  use  of
chloroquine  to  an  artemisinin-based  combination
therapy (ACT)  as  the  ﬁrst  choice  antimalarial
drug for  treatment  of  uncomplicated  malaria.  An
t
t
q
rrtesunate—amodiaquine  combination  is the  anti-
alarial drug  most  used  in  the  selected  study  sites.
he use  of  long  lasting  insecticide-treated  nets
LLINs),  indoor  residual  spraying  (IRS)  and  intermit-
ent preventive  treatment  among  pregnant  women
IPTp) remains  the  major  malaria  intervention
easures in  these  areas.
thical considerations
ll  patients  presenting  with  symptoms  of  malaria  to
he outpatient  department  of  the  selected  health
acility  on  the  day  of  recruitment  were  screened
or study  inclusion.  Only  those  with  P.  falciparum
nfection detected  by  microscopy  were  recruited  too the  adults.  For  children,  both  the  children  and
heir parents  or  guardian  were  encouraged  to  ask
uestions  if  clarity  was  needed.  Patients  were  only
ecruited  after  giving  consent.
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Table  1  Prevalence  of  mutations  in  Pfmdr1  and  Pfcrt  genes  in  Plasmodium  falciparum  isolates.
Polymorphisms  (%)
Gene/codon  position  Wild-type  Mutant  type  Mixed
Pfmdr1
86  137  (64.0)  77  (36.0)  None
184  26  (12.1)  188  (87.9)  None
1034  62  (29.0)  152  (71.0)  None
1042  18  (8.4)  196  (91.6)  None
1246  179  (83.6) 18  (8.4)  17  (7.9)
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ample collection
 total  of  618  patients  were  screened,  out  of  which
17 were  qualiﬁed  to  participate  in  the  study.  Basic
iodata of  all  participants  was  collected  and  a 1  ml
lood sample  was  collected  and  stored  in  tubes  con-
aining EDTA  for  parasitological  analysis.  A  ﬁlter
aper blood  blot  was  prepared  for  each  selected
atient and  later  air-dried  and  stored  at  −20 ◦C  in
ip-locked  plastic  bags  containing  a  silica  gel  for
olecular  analysis.
alaria microscopy
hick  and  thin  blood  ﬁlms  were  prepared  from
he patient’s  blood  samples  and  stained  with  10%
iemsa.  The  slides  were  examined  under  oil  immer-
ion with  the  light  microscope  for  the  presence  of
. falciparum.
etection of Pfcrt and Pfmdr1
olymorphisms
ested  PCR  for  the  ampliﬁcation  of  Pfcrt  and
fmdr1 genes,  followed  by  restriction  fragment
ength polymorphism  (PCR-RFLP),  was  used  to
etect  mutations  in  the  genes  following  published
rotocols [23,24].  Presence  of  mutations  in  Pfcrt  at
osition 76  and  Pfmdr1  at  positions  86,  184,  1034,
042 and  1246  were  determined.
ata analysis
ata  were  organized  using  Microsoft  Ofﬁce  Excel
007 (Microsoft  Corporation)  and  analyzed  with
PSS Statistical  Software  version  16  (SPSS  Inc.).
imple proportion  was  used  to  estimate  the
revalence of  the  mutation.  Statistical  associa-
ion between  polymorphisms  in  Pfmdr1  and  Pfcrt
t codon  76  was  determined  with  Pearson  chi-
quare test.  A  p-value  ≤  0.05  was  considered
5
T
b
g115  (53.7) 39  (18.3)
tatistically  signiﬁcant.  Additionally,  synergism
etween Pfcrt  and  Pfmdr1  gene  was  assessed  using
he Jonckheere—Terpstra  test  and  statistical  signif-
cance was  determined  with  a Monte  Carlo  simu-
ation. The  accuracy  of  synergism  between  Pfcrt
nd Pfmdr1  mutant  genes  was  also  tested  using  the
eceiver Operating  Characteristic  (ROC)  curve.
esults
revalence of point mutations in Pfmdr1
nd Pfcrt gene of the P. falciparum isolates
wo  hundred  and  fourteen  P.  falciparum  isolates
ere analyzed  for  detection  of  mutations  at  N86Y,
184F,  S1034C,  D1042N,  and  D1246Y  of  the  Pfmdr1
ene and  at  codon  76  (K76T)  of  the  Pfcrt  gene.  The
revalence  of  Y86,  F184,  C1034,  Y1246  mutations
f the  Pfmdr1  gene  determined  were  36.0%,  87.9%,
1.0%, 91.6%  and  8.4%,  respectively  (Table  1).
round half  (53.7%)  of  the  examined  isolates  had
he T76  mutation  of  the  Pfcrt  gene  (Table  1).
he prevalence  of  Pfmdr1  haplotypes  in  the  P.
alciparum  isolates  were  mainly  NFCDD  (n  = 93,
3.46%),  YFCDD  (n  = 59,  27.57%),  NFSDD  (n  =  16,
.48%),  NYSNY  (n  = 11,  5.14%)  and  YFSDD  (n  =  10,
.67%; Tables  S1  and  S2).
o-existence of Pfcrt and Pfmdr1 genes
able  2 shows  the  association  of  Pfcrt  alleles  at
odon 76  with  alleles  of  Pfmdr1  at  codon  86,  184,
034, 1042  and  1246.  One  hundred  thirty-seven
f the  total  number  of  isolates  examined  had  the
ild-type  allele  at  codon  86  of  the  Pfmdr1  gene
ogether with  the  Pfcrt  gene,  while  29.2%  had  K76,
5.5%  had  T76  and  15.3%  had  both  the  K76  and
76 alleles.  There  was  no  signiﬁcant  difference
etween the  codon  76  polymorphisms  of  the  Pfcrt
ene and  the  wild-type  allele  at  codon  86  of  the
114  K.K.  Asare  et  al.
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Table  3  Association  of  Pfcrt  76T  mutation  with  the
double  mutation  polymorphisms  of  the  Pfmdr1  gene.
Codon  polymorphisms  Pearson  2 p-Value
Pfmdr1  Pfcrt
86  and  184 76
NY  T
NY  K  4.083  0.665
YY  T
YY  K  6.667  0.155
NF  T
NF  K  8.130  0.229
YF  T
YF  K  18.045  0.006***
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(NB:  The bold and underlined amino acids are mutant alleles.
* signiﬁcant (p < 0.05); ** signiﬁcant (p < 0.01); *** highly sig-
niﬁcant (p < 0.001).
fmdr1  gene  (2 =  10.961,  p  =  0.090).  Seventy-seven
77/214) of  the  isolates  had  the  mutant  allele  at
odon 86  of  Pfmdr1.  A  statistically  signiﬁcant  dif-
erence  was  observed  between  the  isolates  with  a
utation at  codon  86  of  Pfmdr1  co-existing  with
hat at  codon  76  of  Pfcrt  (mutant  allele)  com-
ared to  isolates  with  a mutant  allele  at  codon
6 of  Pfmdr1  co-existing  with  wild-type  allele  at
odon 76  of  the  Pfcrt  gene  (2 =  19.506,  p =  0.003).
imilar trends  were  observed  between  the  muta-
ions at  codon  184,  1034  and  1042  of the  Pfmdr1
nd the  mutant  Pfcrt  gene.  Observations  made
n this  study  indicated  an  association  between  a
fcrt 76T  mutation  with  multiple  mutations  at  86,
84, 86,  184  and  1034  codons  of  the  Pfmdr1  gene.
he association  between  Pfcrt  T76  and  double  and
riple mutations  at  86,  184  and  1034  codon  pos-
tions of  the  Pfmdr1  gene  was  also  discovered.
he results  shown  in  Table  3  indicate  a signiﬁcant
ssociation between  Pfcrt  T76  and  Y86-F184  hap-
otype of  Pfmdr1  (2 =  18.045,  p  =  0.006)  but  not
he NY,  YY  or  NF  haplotypes  of  the  Pfmdr1  iso-
ates when  only  polymorphisms  at  codon  86  and
84 of  Pfmdr1  were  considered.  The  test  of  asso-
iation between  Pfcrt  T76  and  the  triple  codon
aplotype mutations  of  Pfmdr1  showed  a  similar
rend to  that  observed  for  the  double  codon  poly-
orphisms.  Two  levels  of  association  were  observed
or the  triple  haplotype  at  86,  184  and  1034  of
fmdr1  and  Pfcrt  T76,  NFC  (2 = 13.770,  p  =  0.032)
nd YFC  (2 =  16.489,  p  =  0.011),  but  not  with  YFS
2 =  5.511,  p =  0.480;  Table  4).  The  pattern  of  asso-
iation did  not  change  when  haplotypes  for  86,
84, 1034  and  1042  of  Pfmdr1  were  determined.
imilarly, haplotypes  for  86,  184,  1034,  1042  and
246 of  Pfmdr1  showed  an  association  with  Pfcrt
76 as  did  the  triple  haplotypes  of  Pfmdr1:  NFCDD
2 =  13.770,  p =  0.032)  and  YFCDD  (2 = 16.487,
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Table  4  Association  of  Pfcrt  76T  mutation  with  the
triple  mutations  polymorphism  of  the  Pfmdr1  gene.
Codon  polymorphisms  Pearson  2 p-Value
Pfmdr1  Pfcrt
86,  184  and  1034  76
NYS  T
NYS  K  4.083  0.665
YYS  T
YYS  K  6.667  0.155
NFS  T
NFS  K  7.157  0.307
YFS  T
YFS  K  5.511  0.480
NFC  T
NFC  K  13.770  0.032*
YFC  T
YFC  K  16.489  0.011**
NB:  The bold and underlined amino acids are mutant alleles.
* signiﬁcant (p < 0.05); ** signiﬁcant (p < 0.01); *** highly sig-
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Figure  2  ROC  curve  for  true  positive  synergism  rate
against  false  positive  synergism  between  Pfcrt  and
P
P
D
T
f
[
m
P
[
b
s
ﬁ
H
w
o
a
T
a
s
o
W
m
a
t
o
p
a
e
oniﬁcant (p < 0.001).
 =  0.011).  No  association  was  observed  for  YYSNY
2 =  5.000,  p  =  0.287;  Tables  S1  and  S2).
ynergism between Pfcrt and Pfmdr1 gene
he  co-existence  between  the  T76  mutation
f Pfcrt  gene  and  mutations  at  codon  pos-
tions 86,  184,  and  1034  of  Pfmdr1  were  fur-
her tested  for  stochastic  prevalence  using  the
onckheere—Terpstra  test  (J—T).  The  standard  J—T
tatistic  between  the  Pfcrt  at  codon  76  polymor-
hism and  Pfmdr1  at  codon  positions  86,  184,
034, 1042  and  1246  were  6.830,  8.695,  14.264,
.086 and  4.028,  respectively,  with  p  <  0.0001.  A
igniﬁcant  synergism  (p  < 0.0001)  between  Pfcrt  76
utation and  the  ﬁve  point  mutations  of  Pfmdr1
ere also  observed  using  Monte  Carlo  simula-
ion at  a  99%  conﬁdence  interval  using  the  Pfcrt
6 polymorphism  as  a  group  variable  (Table  5).
ccuracy  of  the  synergism  between  the  Pfcrt  and
fmdr1  genes  was  tested  again  using  the  Receiver
perating characteristic  (ROC)  curve.  The  analysis
ndicated  synergism  between  the  Pfcrt  76  muta-
ion and  Pfmdr1-1034  mutation  perfect  (area  under
OC curve  =  0.994  ±  0.005,  p  <  0.0001)  while  that
etween  Pfcrt  76  and  Pfmdr1  at  codon  positions  86,
84, 1042  and  1246  were  also  signiﬁcant,  with  a ROC
rea of  0.750  ±  0.032,  0.717  ±  0.045,  0.650  ±  0.046
nd 0.614  ±  0.039,  respectively.  However,  syner-
ism between  Pfcrt  76  and  Pfmdr1-1042  (p  =  0.001)
nd Pfmdr1-1246  (p  =  0.01)  were  observed  to  be
omparatively  weaker  (Fig.  2  and  Table  6).
a
r
w
tfmdr1  genes.  The  diagonal  segment  is  ties  produced  by
fcrt  76  polymorphism.
iscussion
he  association  between  chloroquine  treatment
ailure and  K76T  mutation  in  Pfcrt  is  well-known
25,26]. The  contribution  of  N86Y  and  D1246Y
utations of  Pfmdr1  to  the  ﬁtness  of  CQ  resistance
. falciparum  strains  has  also  been  documented
27,28]. The  withdrawal  of  CQ  from  Malawi,  Mozam-
ique and  Kenya  led  to  a  rapid  recovery  of  CQ
ensitive P.  falciparum, which  increased  the  limited
tness costs  that  accompany  CQ  resistance  [29,30].
owever, a rapid  recovery  of  CQ  sensitive  strains
as not  observed  within  the  same  time  frame  in
ther disease  endemic  countries,  such  as  Ghana
nd Uganda  after  CQ  withdrawal  [10—12,14,31].
hus, the  principle  objective  for  this  study  became
scertaining  reasons  for  the  slow  recovery  of  CQ
ensitive  P.  falciparum  with  an  increasing  presence
f amodiaquine  and  quinine  resistance  in  Ghana.
e have  previously  shown  that  the  CQ  resistance
arker Pfcrt  T76  remains  very  high  in  Ghana  even
fter several  years  of  CQ  withdrawal  [10,11].  In
he current  study  we  demonstrated  an  association
f the  chloroquine  resistance  marker  with  all  the
oint mutations  in  Pfmdr1;  at  codon  86,  184,  1034
nd 1042,  except  at  codon  1246.  This  ﬁnding  may
xplain the  continuous  presence  of  signiﬁcant  levels
f CQ  resistant  parasites  in  Ghana.
The mutations  of  Pfmdr1  gene  are  complex
nd the  mechanism  for  modulating  P.  falcipa-
um multiple  antimalarial  drug  resistance  is not
ell-understood  [32,33]. The  effect  of  this  muta-
ion changes  unpredictably,  as  different  mutations
116  K.K.  Asare  et  al.
Table  5  Synergism  between  the  Pfcrt  and  Pfmdr1  gene  polymorphism.
Jonckheere—Terpstra  test
Pfmdr1-86  Pfmdr1-184  Pfmdr1-1034  Pfmdr1-1042  Pfmdr1-1246
Number  of  levels  in  Pfcrt-76 2  2 2  2  2
N  214  214  214  214  214
Observed  J—T  statistic  6930.00  6622.00  9180.00  6006.00  5670.00
Mean  J—T  statistic  4620.00  4620.00  4620.00  4620.00  4620.00
Std.  deviation  of  J—T  statistic  338.238  230.241  319.694  195.605  260.661
Std.  J—T  statistic  6.830  8.695  14.264  7.086  4.028
Asymp.  sig.  (2-tailed)  0.0001  0.0001  0.0001  0.0001  0.0001
Monte  Carlo  sig.
(2-tailed)
Sig.  0.0001  0.0001  0.0001  0.0001  0.0001
99%  CI Lower  bound  0.0  0.0  0.0  0.0  0.0
Upper  bound  0.0  0.0  0.0  0.0  0.001
Monte  Carlo  sig.
(1-tailed)
99%  CI Lower  bound  0.0  0.0  0.0  0.0  0.0
Upper  bound  0.0  0.0  0.0  0.0  0.0
Sig.  0.0001  0.0001  0.0001  0.0001  0.0001
Table  6  Area  under  the  synergism  ROC  curve.
Variable(s)  Area  ±  SEa Asymptotic  95%  CI  Asymptotic  p-Valueb
Pfmdr1-86  0.750  ±  0.032  0.687—0.813  0.0001
Pfmdr1-184  0.717  ±  0.045  0.629—0.804  0.0001
Pfmdr1-1034  0.994  ±  0.005  0.983—1.004  0.0001
Pfmdr1-1042  0.650  ±  0.046  0.560—0.740  0.001
Pfmdr1-1246  0.614  ±  0.039  0.537—0.691  0.010
The test result variable(s): Pfmdr1-86, Pfmdr1-184, Pfmdr1-1034, Pfmdr1-1042, and Pfmdr1-1246 have at least one tie between
the positive actual state group and the negative actual state group.
a
m
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qUnder the nonparametric assumption.
b Null hypothesis: true area = 0.5.
can  increase  the  parasite’s  susceptibility  toward
one antimalarial  drug  or  simultaneously  confer
resistance  to  another  [34,35]. For  instance,  the
N86Y-Y184F-D1246Y  mutation  of  Pfmdr1  polymor-
phism  causes  P.  falciparum  to  be  susceptible  to
artemisinin-based  combination  therapy,  whereas
NFCDY  or  NFSDD  haplotypes  at  codon  86,  184,  1034,
1042, and  1246  are  associated  with  AQ  failure  in
South America  [36—39].
To understand  the  complexities  of  mutant
Pfmdr1 genes  and  their  relationship  with  the
mutant  Pfcrt  gene  at  codon  76,  we  tested  for  syn-
ergism  between  them  using  statistical  methods.
The results  indicated  a  strong  synergic  interaction
between Pfcrt  76  polymorphism  and  that  of  Pfmdr1
at 86,  184,  1034,  1042  and  1246.  When  the  accuracy
of the  synergy  was  veriﬁed  using  ROC,  the  outcome
showed a  stronger  synergy  between  Pfcrt  76  poly-
morphism  and  that  of  Pfmdr1  at  codon  1034,  86,
and 184  but  was  comparatively  weaker  with  that  at
codon 1042  and  1246.
Amodiaquine  and  quinine  are  important  anti-
malarial drugs  in  Ghana.  The  former  is  a co-partner
in the  ﬁrst  line  of  treatment  of  uncomplicated
t
c
a
talaria  using  ACT,  and  the  latter  is  the  drug  of
hoice for  the  management  of  complicated  malaria.
owever,  recent  reports  indicate  some  degree  of
arasite resistance  to  these  drugs.  In  an  attempt
o understand  the  mechanism  of  resistance  to
hese drugs  in  Ghana,  we  examined  the  association
etween Pfcrt  K76T  and  double  mutational  haplo-
ypes at  86  and  184  of  the  Pfmdr1  gene.  The  results
howed that  Pfcrt  T76  was  strongly  associated  with
he double  mutation  YF  haplotype  but  not  in  NY,
Y or  NF.  This  unique  association  has  not  been  pre-
iously reported,  although  individually  the  86Y  of
fmdr1 has  been  reported  to  be  associated  with
Q or  amodiaquine  resistance,  whereas  184F  and
042D have  been  shown  to  have  less  sensitivity  to
N [40,41]. Double  mutation  at  184  and  1042  of
fmdr1 gene  has  been  reported  to  reduce  P.  falcip-
rum  sensitivity  to  quinine  whereas  mutation  at  86
nd 1042  increases  the  parasite’s  susceptibility  to
uinine treatment  [42,43]. This  means  that  modula-
ion of  quinine  resistance  could  depend  on  speciﬁc
ombinations  of  mutations  of  Pfmdr1.  For  instance,
 single  mutation  at  codon  86  has  been  shown
o increase  P.  falciparum  susceptibility  to  quinine
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Nynergism  between  Pfcrt  and  Pfmdr1  genes  in  the  r
43].  However,  a  N1042D  mutation  of  Pfmdr1  can
ither increase  or  reduce  the  parasite’s  suscepti-
ility to  quinine  [42]. Furthermore,  the  insertion
r deletion  of  haplotype  mutations  1034C,  1042D
nd 1246Y  of  Pfmdr1  resulted  in  either  quinine-
esistance or  quinine  sensitive  P.  falciparum  strains
43].  This  tends  to  suggest  that  the  Pfcrt  T76  &  YFC
aplotype  of  Pfmdr1  could  contribute  to  the  emer-
ence of  quinine  resistance  in  Ghana.  Although
uinine remains  the  antimalarial  drug  of  choice  for
he management  of  complicated  malaria  in  Ghana,
he recent  report  of  an  elevated  IC50 value  [13,14]
or  the  drug,  in  addition  to  the  observations  made  in
his study,  should  be  a  matter  of  concern  to  stake-
olders.
From the  data  gathered  in  this  study,  it  is
easonable to  assert  the  association  of  Pfcrt-T76
ith a  N86-F184-C1034  mutation  of  Pfmdr1  may
e responsible  for  the  presence  of  amodiaquine
esistance  in  Ghana.  This  assertion  is  justiﬁed  by
eld-base  report  of  strains  of  P.  falciparum  carry-
ng either  CVIET  or  SVMNT  at  codon  72—76  of  the
fcrt gene  and  NFCDY  or  NFSDD  at  codon  86,  184,
034, 1042,  1246  of  the  Pfmdr1  gene  [42], as  well
s an  association  with  high  in  vitro  IC50 values  for
onodesethylamodiaquine.
P. falciparum  strains  with  the  N86,  F184  and
1246 (NFD)  haplotype  have  been  reported  to  have
 ﬁtness  advantage  under  artemether-lumefantrine
AL)  pressure  [39].  Thus,  the  observed  increase  in
revalence of  NFD  in  Tanzania  and  Mozambique
fter the  introduction  of  AL  could  involve  NFD
nder AL  pressure.  Based  on  observations  made
n this  study,  is  possible  artemether-lumefantrine
esistant P.  falciparum  may  emerge  in  Ghana  in
he near  future.  The  reported  high  variation  in
atient  response  to  treatment  with  artemether-
umefantrine  in  different  ecological  zones  [41]
ould  signify  an  onset  of  resistance  to  the  combina-
ion antimalarial  drug.
Several  reports  have  shown  that  integrated  vec-
or control  strategies,  such  as  the  use  of  long  lasting
nsecticide-treated  nets  (LLIN)  and  indoor  residual
praying  (IRS),  have  resulted  in  reduced  malaria
orbidity and  mortality  especially  among  children
44—46].  In  Ghana,  vector  control  programs  have
een in  place  since  2005  but  have  not  had  any
igniﬁcant impact  on  disease  prevalence  until  a
ecent refocus  of  efforts.  New  efforts  involve  not
nly free  distribution  of  LLIN,  but  a  door-to-door
ampaign to  hang  these  nets  by  community-based
olunteers  to  enhance  usage.  Additionally,  indoor
esidual  spraying  in  communities,  including  the
tudy areas,  has  been  ongoing.  These  interventional
easures appear  to  have  positive  impact,  as  lat-
st reports  from  the  NMCP  indicate  the  malaria
E
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revalence  rate  is  declining  in  Ghana  [47].  Despite
he clear  public  health  beneﬁt  of  the  vector  con-
rol measures,  the  impact  of  these  measures  on  the
pread of  drug  resistance  P. falcipaum  is  not  well
nderstood.  In  2011,  Shi  et  al.  reported  there  is  no
vidence to  suggest  sustained  transmission  reduc-
ion by  LLIN  usage  reduces  the  prevalence  of  the
enes associated  with  malaria  drug  resistance  [48].
he inﬂuence  of  these  vector  control  measures  on
he study  ﬁndings  could  not  be  immediately  deter-
ined.
Observations  made  in  this  study  strongly  sug-
est the  slow  recovery  of  chloroquine  sensitive
. falciparum  strains  and  the  presence  of  amodi-
quine  and  quinine  resistance  in  Ghana  could  be
ue to  synergism  between  Pfcrt  and  Pfmdr1  mutant
enes.  It  must  be  emphasized  that  this  could  be
aused by  indiscriminate  use  of  CQ  with  the  resul-
ant selection  for  resistant  strains  of  the  parasite.
hloroquine is  a safe  and  affordable  drug,  and  with
ains in  efﬁcacy,  could  be  adapted  for  use  as  one
f the  partners  in  a drug  combination  therapy.  It
s therefore  imperative  to  put  measures  in  place
o ensure  the  fast  restoration  of  chloroquine  use  in
hana.
onclusions
indings  from  this  study  suggest  synergism  between
utant  Pfcrt  and  Pfmdr1  genes  in  P.  falciparum
ould account  for  the  slow  recovery  of  chloroquine
ensitive parasites  long  after  the  disuse  of  chloro-
uine  in  Ghana.  This  phenomenon  could  also  be
esponsible  for  the  presence  of  quinine  and  amodi-
quine  resistance  in  the  country.  From  the  gathered
ata,  if  the  right  preventive  measures  are  not  put
n place,  artemether-lumefantrine  resistance  could
merge in  Ghana  sooner  rather  than  later.
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